Enhanced Neoepitope-Specific Immunity Following Neoadjuvant PD-L1 and TGF-B Blockade in HPV-Unrelated Head and Neck Cancer

Scientists conducted a clinical trial in 14 patients with newly diagnosed, human papillomavirus-unrelated head and neck squamous cell carcinoma to evaluate the safety and efficacy of neoadjuvant bintrafusp alfa, a bifunctional fusion protein that blocked programmed death-ligand 1 (PD-L1) and neutralized transforming growth factor-beta (TGF-b).